Delivering genetic therapies like CRISPR to the brain is challenging due to difficulty targeting specific cells and limited efficiency of delivery vectors.

“And, you know, you very often, the way you deliver this, like through a virus or through other modalities, there's only so much of that virus that you can actually put inside the nervous system. And the efficiency is not yet very high.”